Fate Therapeutics Inc. Common Stock (FATE)
Stock · NASDAQ · Health Care
$1.78as of 10/16/2026
Price chart
Active signals
FATE Signal Track Record
How signals performed across all stocks →What FATE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -9.1% | 39% | October 5, 2026 |
| Bollinger Band Breakout | 22 | -15.0% | 36% | June 30, 2026 |
| Bollinger Band BreakdownActive now | 19 | +3.1% | 53% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +1.2% | 50% | March 27, 2026 |
| Any 20-session window (baseline) | -5.8% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell progr…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 161
- Website
- fatetherapeutics.com/
Fundamentals
- 1-day range
- $1.91$2
- Market cap
- $290.23M
- P/E (trailing)
- —
- P/E (forward)
- -1.99
- EPS (trailing)
- $-1.05
- Dividend yield
- —
- Beta
- 2.67
- Avg. volume
- 1.67M
How Fate Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Fate Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesYahoo · 10/1/2026
- Sector Update: Healthcare Stocks Edge Higher Premarket FridayYahoo · 9/25/2026
- Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LNYahoo · 9/25/2026
- Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus NephritisBenzinga · 9/25/2026
- Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026Yahoo · 9/16/2026
- Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026Benzinga · 9/16/2026
Insider Activity
Insider Actions →- TAHL CINDY · August 4, 2026 · Sale38.8K @ $2.46
- Valamehr Bahram · August 4, 2026 · Sale43.9K @ $2.46
- Jooss Karin · June 12, 2026 · Grant87.9K
- Agarwal Shefali · June 12, 2026 · Grant87.9K
- Robert S. Epstein · June 12, 2026 · Grant87.9K
- William H. Rastetter · June 12, 2026 · Grant87.9K
- Lee Michael Stewart · June 12, 2026 · Grant87.9K
- Xu Yuan · June 12, 2026 · Grant87.9K
- Matt Abernethy · June 12, 2026 · Grant87.9K
- Laura Hamill · June 12, 2026 · Grant175.8K
- Redmile Group, LLC · June 12, 2026 · Grant87.9K
- TAHL CINDY · May 20, 2026 · Sale25.6K @ $1.88
- Valamehr Bahram · May 20, 2026 · Sale28.9K @ $1.88
- TAHL CINDY · May 6, 2026 · Option Exercise44.4K @ $1.05
- TAHL CINDY · May 6, 2026 · Option Exercise122.2K @ $1.32
Institutional Ownership
March 31, 2026
- Total shares held
- 69.35M
- Total value held
- $77.53M
- Institutional holders
- 151
- Unknown12.87M
- Unknown10.07M
- Unknown4.19M
- Unknown4.12M
- Unknown3.47M
- Unknown3.38M
- Unknown3.00M
- Unknown2.97M
- Unknown2.59M
- Unknown2.26M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.